Neurocrine Biosciences, Inc. (0K6R.L)
USD 138.27
(1.59%)
USD 138.27
(1.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 416.1 Million USD | 67.11% |
| 2022 | 264.6 Million USD | 19.83% |
| 2021 | 218.7 Million USD | -36.55% |
| 2020 | 336.1 Million USD | 44.53% |
| 2019 | 226.6 Million USD | 514.18% |
| 2018 | 56.39 Million USD | 128.08% |
| 2017 | -120.61 Million USD | 14.49% |
| 2016 | -139.59 Million USD | -54.47% |
| 2015 | -87.92 Million USD | -45.71% |
| 2014 | -63.58 Million USD | -28.19% |
| 2013 | -49 Million USD | -2417.73% |
| 2012 | 2.1 Million USD | -106.95% |
| 2011 | 34.61 Million USD | 347.74% |
| 2010 | -13.72 Million USD | 72.29% |
| 2009 | -47.85 Million USD | 32.44% |
| 2008 | -73.97 Million USD | 39.71% |
| 2007 | -193.97 Million USD | -5.92% |
| 2006 | -102.75 Million USD | -586.01% |
| 2005 | -14.97 Million USD | 66.8% |
| 2004 | -45.25 Million USD | 38.35% |
| 2003 | -55.09 Million USD | 27.35% |
| 2002 | -100.51 Million USD | -141.79% |
| 2001 | -41.23 Million USD | -20.93% |
| 2000 | -33.4 Million USD | -91.39% |
| 1999 | -17.8 Million USD | -445.45% |
| 1998 | -10.7 Million USD | -6.45% |
| 1997 | 1.8 Million USD | -720.0% |
| 1996 | 3.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 191.3 Million USD | 23.26% |
| 2024 Q1 | 111.5 Million USD | -28.53% |
| 2024 Q2 | 155.2 Million USD | 39.19% |
| 2023 Q2 | 73.6 Million USD | 147.81% |
| 2023 FY | - USD | 67.11% |
| 2023 Q1 | 29.7 Million USD | -71.28% |
| 2023 Q4 | 156 Million USD | 10.48% |
| 2023 Q3 | 141.2 Million USD | 91.85% |
| 2022 Q1 | 6.4 Million USD | -90.0% |
| 2022 Q4 | 103.4 Million USD | 12.64% |
| 2022 Q3 | 91.8 Million USD | 56.66% |
| 2022 Q2 | 58.6 Million USD | 815.63% |
| 2022 FY | - USD | 19.83% |
| 2021 Q3 | 47.3 Million USD | -32.81% |
| 2021 Q4 | 64 Million USD | 35.31% |
| 2021 Q2 | 70.4 Million USD | 107.06% |
| 2021 FY | - USD | -36.55% |
| 2021 Q1 | 34 Million USD | -52.65% |
| 2020 Q2 | 124.7 Million USD | 104.43% |
| 2020 FY | - USD | 44.53% |
| 2020 Q3 | 74.2 Million USD | -40.5% |
| 2020 Q4 | 71.8 Million USD | -3.23% |
| 2020 Q1 | 61 Million USD | -28.24% |
| 2019 FY | - USD | 514.18% |
| 2019 Q2 | 41.24 Million USD | 202.18% |
| 2019 Q3 | 92.1 Million USD | 123.31% |
| 2019 Q4 | 85 Million USD | -7.72% |
| 2019 Q1 | 13.65 Million USD | -37.59% |
| 2018 Q4 | 21.87 Million USD | -60.52% |
| 2018 Q2 | -969 Thousand USD | 97.36% |
| 2018 Q1 | -36.66 Million USD | -410.5% |
| 2018 FY | - USD | 128.08% |
| 2018 Q3 | 55.4 Million USD | 5817.54% |
| 2017 Q1 | -81.04 Million USD | -69.45% |
| 2017 Q3 | -5.37 Million USD | 90.51% |
| 2017 FY | - USD | 14.49% |
| 2017 Q4 | 11.8 Million USD | 319.5% |
| 2017 Q2 | -56.67 Million USD | 30.07% |
| 2016 FY | - USD | -54.47% |
| 2016 Q2 | -43.05 Million USD | -94.16% |
| 2016 Q3 | -39.57 Million USD | 8.07% |
| 2016 Q4 | -47.83 Million USD | -20.85% |
| 2016 Q1 | -22.17 Million USD | 31.07% |
| 2015 Q2 | -26.4 Million USD | -744.45% |
| 2015 Q3 | -37 Million USD | -40.15% |
| 2015 Q4 | -32.17 Million USD | 13.08% |
| 2015 Q1 | -3.12 Million USD | 85.44% |
| 2015 FY | - USD | -45.71% |
| 2014 Q3 | -17.83 Million USD | -17.9% |
| 2014 Q4 | -21.47 Million USD | -20.39% |
| 2014 Q2 | -15.13 Million USD | -11.92% |
| 2014 FY | - USD | -28.19% |
| 2014 Q1 | -13.51 Million USD | -9.0% |
| 2013 Q1 | -13.69 Million USD | -278.38% |
| 2013 FY | - USD | -2417.73% |
| 2013 Q4 | -12.4 Million USD | 2.48% |
| 2013 Q3 | -12.71 Million USD | 9.72% |
| 2013 Q2 | -14.08 Million USD | -2.85% |
| 2012 Q3 | -4.68 Million USD | -123.75% |
| 2012 Q4 | 7.67 Million USD | 263.98% |
| 2012 FY | - USD | -106.95% |
| 2012 Q1 | -2.54 Million USD | -763.05% |
| 2012 Q2 | -2.09 Million USD | 17.79% |
| 2011 Q2 | 368 Thousand USD | -70.23% |
| 2011 Q4 | -295 Thousand USD | -101.01% |
| 2011 FY | - USD | 347.74% |
| 2011 Q3 | 29.34 Million USD | 7873.37% |
| 2011 Q1 | 1.23 Million USD | 297.13% |
| 2010 Q3 | 1.95 Million USD | 130.63% |
| 2010 Q2 | -6.39 Million USD | 40.31% |
| 2010 Q1 | -10.7 Million USD | -16.91% |
| 2010 FY | - USD | 72.29% |
| 2010 Q4 | -627 Thousand USD | -132.04% |
| 2009 Q4 | -9.15 Million USD | 4.06% |
| 2009 Q3 | -9.54 Million USD | 31.63% |
| 2009 FY | - USD | 32.44% |
| 2009 Q1 | -7.6 Million USD | 73.91% |
| 2009 Q2 | -13.96 Million USD | -83.6% |
| 2008 Q1 | -18.69 Million USD | 85.21% |
| 2008 Q2 | -18.11 Million USD | 3.09% |
| 2008 Q3 | -13.73 Million USD | 24.19% |
| 2008 FY | - USD | 39.71% |
| 2008 Q4 | -29.14 Million USD | -112.19% |
| 2007 FY | - USD | -5.92% |
| 2007 Q4 | -126.42 Million USD | -375.03% |
| 2007 Q3 | -26.61 Million USD | -6.11% |
| 2007 Q2 | -25.08 Million USD | -1.49% |
| 2007 Q1 | -24.71 Million USD | -80.6% |
| 2006 Q4 | -13.68 Million USD | 63.11% |
| 2006 Q1 | -24.92 Million USD | -13.36% |
| 2006 FY | - USD | -586.01% |
| 2006 Q3 | -37.09 Million USD | -39.58% |
| 2006 Q2 | -26.57 Million USD | -6.6% |
| 2005 Q1 | -16.9 Million USD | 9.94% |
| 2005 FY | - USD | 66.8% |
| 2005 Q2 | -3.73 Million USD | 77.9% |
| 2005 Q3 | 27.69 Million USD | 841.19% |
| 2005 Q4 | -21.99 Million USD | -179.42% |
| 2004 Q4 | -18.77 Million USD | -1894.69% |
| 2004 Q3 | -941 Thousand USD | 92.11% |
| 2004 Q2 | -11.92 Million USD | 11.62% |
| 2004 Q1 | -13.48 Million USD | 60.95% |
| 2004 FY | - USD | 38.35% |
| 2003 FY | - USD | 27.35% |
| 2003 Q4 | -16.57 Million USD | -174.65% |
| 2003 Q3 | -12.55 Million USD | -9.0% |
| 2003 Q2 | -11.48 Million USD | 20.62% |
| 2003 Q1 | -14.48 Million USD | 64.03% |
| 2002 FY | - USD | -141.79% |
| 2002 Q4 | -40.36 Million USD | -86.17% |
| 2002 Q1 | -17.12 Million USD | -17.52% |
| 2002 Q2 | -21.31 Million USD | -24.13% |
| 2002 Q3 | -21.71 Million USD | -1.44% |
| 2001 Q4 | -14.67 Million USD | -942.33% |
| 2001 Q3 | 1.88 Million USD | 111.48% |
| 2001 Q2 | -14.95 Million USD | -11.78% |
| 2001 Q1 | -13.48 Million USD | -25.05% |
| 2001 FY | - USD | -20.93% |
| 2000 FY | - USD | -91.39% |
| 2000 Q1 | -6.7 Million USD | -30.04% |
| 2000 Q3 | -9.12 Million USD | -23.36% |
| 2000 Q4 | -10.73 Million USD | -15.39% |
| 2000 Q2 | -6.84 Million USD | -19.63% |
| 1999 FY | - USD | -445.45% |
| 1999 Q4 | -4.4 Million USD | -8.89% |
| 1999 Q2 | -4.89 Million USD | -31.82% |
| 1999 Q1 | -3.9 Million USD | -174.58% |
| 1999 Q3 | -4.5 Million USD | 22.41% |
| 1998 Q2 | -3 Million USD | 115.15% |
| 1998 Q3 | -2.6 Million USD | -1360.0% |
| 1998 Q4 | -200 Thousand USD | 193.65% |
| 1998 FY | - USD | -6.45% |
| 1998 Q1 | -2 Million USD | -50.0% |
| 1997 Q4 | -900 Thousand USD | -57.14% |
| 1997 Q1 | 3.4 Million USD | 0.0% |
| 1997 FY | - USD | -720.0% |
| 1997 Q3 | -100 Thousand USD | 12.5% |
| 1997 Q2 | -500 Thousand USD | -169.57% |
| 1996 Q2 | 1.5 Million USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q3 | -1.2 Million USD | -340.0% |
| 1996 Q4 | 3.6 Million USD | 195.83% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 355.093% |
| Dynavax Technologies Corporation | 9.66 Million USD | -4204.78% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -323.46% |
| Perrigo Company plc | 646.2 Million USD | 35.608% |
| Illumina, Inc. | -608 Million USD | 168.438% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 96.147% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 192.67% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 103.689% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 87.221% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 500.898% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 91.06% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 1216.058% |
| Waters Corporation | 1.02 Billion USD | 59.296% |
| Biogen Inc. | 2.37 Billion USD | 82.495% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 575.94% |
| Evolus, Inc. | -41.81 Million USD | 1095.216% |
| Adicet Bio, Inc. | -136.53 Million USD | 404.757% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 453.676% |
| bluebird bio, Inc. | -167.16 Million USD | 348.922% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 377.2% |
| FibroGen, Inc. | -261.4 Million USD | 259.178% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 75.188% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 1036.388% |
| Homology Medicines, Inc. | -47.75 Million USD | 971.304% |
| Geron Corporation | -174.78 Million USD | 338.068% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 282.403% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 551.895% |
| Myriad Genetics, Inc. | -67.8 Million USD | 713.717% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 512.687% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 182.182% |
| Zoetis Inc. | 3.68 Billion USD | 88.708% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 922.787% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 64.254% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -34.103% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 90.965% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 1253.207% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 280.905% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 256.43% |
| Verastem, Inc. | -83.16 Million USD | 600.325% |
| Nektar Therapeutics | -243.1 Million USD | 271.159% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 284.941% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 572.922% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 194.741% |
| OPKO Health, Inc. | -65.51 Million USD | 735.112% |
| Exelixis, Inc. | 196.6 Million USD | -111.646% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -284.125% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 846.287% |
| uniQure N.V. | -253.1 Million USD | 264.401% |
| Imunon, Inc. | -20.78 Million USD | 2102.187% |
| Blueprint Medicines Corporation | -474.61 Million USD | 187.672% |
| Insmed Incorporated | -654.73 Million USD | 163.552% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 7.932% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 220.446% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1494.253% |
| Incyte Corporation | 919.42 Million USD | 54.744% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 182.347% |